Chemical: Drug

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

Annotated Labels

  1. Annotation of FDA Label for eltrombopag and F5,SERPINC1
  2. Annotation of EMA Label for eltrombopag and F5,SERPINC1
  3. Annotation of PMDA Label for eltrombopag and SERPINC1
  4. Annotation of HCSC Label for eltrombopag and F5,SERPINC1

last updated 10/25/2013

2. Annotation of EMA Label for eltrombopag and F5,SERPINC1

Actionable PGx


The EMA European Public Assessment Report (EPAR) highlights that caution should be taken when administering eltrombopag in patients with known risk factors for thromboembolism, including Factor V Leiden (F5 gene) and ATIII deficiency (SERPINC1 gene).

There's more of this label. Read more.

4. Annotation of HCSC Label for eltrombopag and F5,SERPINC1

Actionable PGx


The product monograph for eltrombopag (REVOLADE) states that caution should be used when administering the drug to patients with risk factors for thromboembolism, such as Factor V Leiden mutation (rs6025 in F5) and antithrombin III deficiency (SERPINC1).

There's more of this label. Read more.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help


Generic Names
  • Eltrombopag olamine
Trade Names
  • Promacta
  • Revolade
Brand Mixture Names

PharmGKB Accession Id





Eltrombopag is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy (excerpt from drug label).

Source: PharmGKB

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Chemical Properties

Chemical Formula


Source: PubChem Compound

Canonical SMILES


Source: PubChem Compound

Average Molecular Weight


Source: PubChem Compound

Monoisotopic Molecular Weight


Source: PubChem Compound


  • 2-aminoethanol; 3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.
No related diseases are available


PubChem Compound:

Clinical Trials

These are trials that mention eltrombopag and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.